AM-1241
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 524172

CAS#: 444912-48-5

Description: AM-1241 is a chemical from the aminoalkylindole family that acts as a potent and selective agonist for the cannabinoid receptor CB2. It has analgesic effects in animal studies, particularly against "atypical" pain such as hyperalgesia and allodynia.


Chemical Structure

img
AM-1241
CAS# 444912-48-5

Theoretical Analysis

MedKoo Cat#: 524172
Name: AM-1241
CAS#: 444912-48-5
Chemical Formula: C22H22IN3O3
Exact Mass: 503.07
Molecular Weight: 503.330
Elemental Analysis: C, 52.50; H, 4.41; I, 25.21; N, 8.35; O, 9.54

Price and Availability

Size Price Availability Quantity
5mg USD 275 2 Weeks
10mg USD 475 2 Weeks
25mg USD 850 2 Weeks
Bulk inquiry

Synonym: AM-1241; AM 1241; AM1241; UNII-DLM851L3RD.

IUPAC/Chemical Name: (1-(Methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole)

InChi Key: ZUHIXXCLLBMBDW-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H22IN3O3/c1-24-11-5-4-6-16(24)13-25-14-19(17-7-2-3-8-21(17)25)22(27)18-12-15(26(28)29)9-10-20(18)23/h2-3,7-10,12,14,16H,4-6,11,13H2,1H3

SMILES Code: CN1CCCCC1Cn2cc(c3c2cccc3)C(=O)c4cc(ccc4I)[N+](=O)[O-]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Biological target: AM-1241 is a selective cannabinoid CB2 receptor agonist with Ki of 3.4 nM, exhibits 82-fold selectivity over CB1 receptor.
In vitro activity: Pretreatment with AM1241 significantly and dose-dependently prevented the H2O2-induced reduction of cell viability (Fig. 5A). Reactive oxygen species levels significantly and dose-dependently decreased in the presence of AM1241 (Fig. 5B, C). with AM1241 before H2O2 exposure significantly and dose-dependently protected myoblasts against apoptosis (Fig. 5D). Western blot revealed a significant increase in the protein levels of cleaved caspase 3, a marker of apoptosis, in H2O2-treated myoblasts compared with control myoblasts, and pretreatment with AM1241 significantly decreased cleaved caspase 3 protein levels (Fig. 5E). Immunofluorescent staining showed that Nrf2 in control myoblasts was mainly localized in the cytoplasm but translocated to nuclei after AM1241 treatment (Fig. 5F). Western blot showed that non-cytotoxic concentrations of AM1241 dose-dependently increased Nrf2 and HO-1 protein expression and accumulation of Nrf2 in the nuclear fraction (Fig. 5G). Reference: Life Sci. 2019 Aug 1;230:55-67. https://pubmed.ncbi.nlm.nih.gov/31989652/
In vivo activity: ELISA results showed that compared with sham group, the serum levels of cTnI, CK-MB, AST and LDH were significantly increased in the I/R group (P < 0.05), indicating that myocardial injury occurred in rats exposed to I/R. However, AM1241 significantly alleviated the upward trend in a dose-dependent way (P < 0.05) (Fig. 1A). In addition, EB/TTC staining results showed that AM1241 treatment significantly reduced the large area of myocardial infarction induced by I/R (P < 0.05) (Fig. 1B). Reference: Life Sci. 2021 May 1;272:119228. https://pubmed.ncbi.nlm.nih.gov/33607150/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 55.5 110.27
DMF 25.0 49.67
DMF:PBS (pH 7.2) (1:2) 0.3 0.60
Ethanol 5.0 9.93

Preparing Stock Solutions

The following data is based on the product molecular weight 503.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Zhang M, Zhang M, Wang L, Yu T, Jiang S, Jiang P, Sun Y, Pi J, Zhao R, Guan D. Activation of cannabinoid type 2 receptor protects skeletal muscle from ischemia-reperfusion injury partly via Nrf2 signaling. Life Sci. 2019 Aug 1;230:55-67. doi: 10.1016/j.lfs.2019.05.056. Epub 2019 May 22. PMID: 31128135. 2. Han D, Li X, Fan WS, Chen JW, Gou TT, Su T, Fan MM, Xu MQ, Wang YB, Ma S, Qiu Y, Cao F. Activation of cannabinoid receptor type II by AM1241 protects adipose-derived mesenchymal stem cells from oxidative damage and enhances their therapeutic efficacy in myocardial infarction mice via Stat3 activation. Oncotarget. 2017 May 4;8(39):64853-64866. doi: 10.18632/oncotarget.17614. PMID: 29029396; PMCID: PMC5630296. 3. Liu W, Chen C, Gu X, Zhang L, Mao X, Chen Z, Tao L. AM1241 alleviates myocardial ischemia-reperfusion injury in rats by enhancing Pink1/Parkin-mediated autophagy. Life Sci. 2021 May 1;272:119228. doi: 10.1016/j.lfs.2021.119228. Epub 2021 Feb 16. PMID: 33607150. 4. Ali AM, El-Tawil OS, Al-Mokaddem AK, Abd El-Rahman SS. Promoted inhibition of TLR4/miR-155/ NFkB p65 signaling by cannabinoid receptor 2 agonist (AM1241), aborts inflammation and progress of hepatic fibrosis induced by thioacetamide. Chem Biol Interact. 2021 Feb 25;336:109398. doi: 10.1016/j.cbi.2021.109398. Epub 2021 Jan 24. PMID: 33503444.
In vitro protocol: 1. Zhang M, Zhang M, Wang L, Yu T, Jiang S, Jiang P, Sun Y, Pi J, Zhao R, Guan D. Activation of cannabinoid type 2 receptor protects skeletal muscle from ischemia-reperfusion injury partly via Nrf2 signaling. Life Sci. 2019 Aug 1;230:55-67. doi: 10.1016/j.lfs.2019.05.056. Epub 2019 May 22. PMID: 31128135. 2. Han D, Li X, Fan WS, Chen JW, Gou TT, Su T, Fan MM, Xu MQ, Wang YB, Ma S, Qiu Y, Cao F. Activation of cannabinoid receptor type II by AM1241 protects adipose-derived mesenchymal stem cells from oxidative damage and enhances their therapeutic efficacy in myocardial infarction mice via Stat3 activation. Oncotarget. 2017 May 4;8(39):64853-64866. doi: 10.18632/oncotarget.17614. PMID: 29029396; PMCID: PMC5630296.
In vivo protocol: 1. Liu W, Chen C, Gu X, Zhang L, Mao X, Chen Z, Tao L. AM1241 alleviates myocardial ischemia-reperfusion injury in rats by enhancing Pink1/Parkin-mediated autophagy. Life Sci. 2021 May 1;272:119228. doi: 10.1016/j.lfs.2021.119228. Epub 2021 Feb 16. PMID: 33607150. 2. Ali AM, El-Tawil OS, Al-Mokaddem AK, Abd El-Rahman SS. Promoted inhibition of TLR4/miR-155/ NFkB p65 signaling by cannabinoid receptor 2 agonist (AM1241), aborts inflammation and progress of hepatic fibrosis induced by thioacetamide. Chem Biol Interact. 2021 Feb 25;336:109398. doi: 10.1016/j.cbi.2021.109398. Epub 2021 Jan 24. PMID: 33503444.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Yu SJ, Reiner D, Shen H, Wu KJ, Liu QR, Wang Y. Time-Dependent Protection of CB2 Receptor Agonist in Stroke. PLoS One. 2015 Jul 17;10(7):e0132487. doi: 10.1371/journal.pone.0132487. eCollection 2015. PubMed PMID: 26186541; PubMed Central PMCID: PMC4505877.

2: Bujalska-Zadrożny M, de Cordé A, Pawlik K. Influence of nitric oxide synthase or cyclooxygenase inhibitors on cannabinoids activity in streptozotocin-induced neuropathy. Pharmacol Rep. 2015 Apr;67(2):209-16. doi: 10.1016/j.pharep.2014.08.023. Epub 2014 Sep 16. PubMed PMID: 25712641.

3: Ma L, Jia J, Liu X, Bai F, Wang Q, Xiong L. Activation of murine microglial N9 cells is attenuated through cannabinoid receptor CB2 signaling. Biochem Biophys Res Commun. 2015 Feb 27;458(1):92-7. doi: 10.1016/j.bbrc.2015.01.073. Epub 2015 Jan 27. PubMed PMID: 25637536.

4: Janero DR, Makriyannis A. Terpenes and lipids of the endocannabinoid and transient-receptor-potential-channel biosignaling systems. ACS Chem Neurosci. 2014 Nov 19;5(11):1097-106. doi: 10.1021/cn5000875. Epub 2014 Jun 5. Review. PubMed PMID: 24866555.

5: Greco R, Mangione AS, Sandrini G, Nappi G, Tassorelli C. Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model. J Headache Pain. 2014 Mar 17;15:14. doi: 10.1186/1129-2377-15-14. PubMed PMID: 24636539; PubMed Central PMCID: PMC3995520.

6: Wang Y, Ma S, Wang Q, Hu W, Wang D, Li X, Su T, Qin X, Zhang X, Ma K, Chen J, Xiong L, Cao F. Effects of cannabinoid receptor type 2 on endogenous myocardial regeneration by activating cardiac progenitor cells in mouse infarcted heart. Sci China Life Sci. 2014 Feb;57(2):201-8. doi: 10.1007/s11427-013-4604-z. Epub 2014 Jan 15. PubMed PMID: 24430557.

7: Avraham HK, Jiang S, Fu Y, Rockenstein E, Makriyannis A, Zvonok A, Masliah E, Avraham S. The cannabinoid CB₂ receptor agonist AM1241 enhances neurogenesis in GFAP/Gp120 transgenic mice displaying deficits in neurogenesis. Br J Pharmacol. 2014 Jan;171(2):468-79. doi: 10.1111/bph.12478. PubMed PMID: 24148086; PubMed Central PMCID: PMC3904265.

8: Cui JH, Ju J, Yoon MH. Pharmacology of cannabinoid receptor agonists and a cyclooxygenase-2 inhibitor in rat bone tumor pain. Pharmacology. 2013;92(3-4):150-7. doi: 10.1159/000354296. Epub 2013 Sep 4. PubMed PMID: 24008428.

9: Marini P, Cascio MG, King A, Pertwee RG, Ross RA. Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors. Br J Pharmacol. 2013 Jun;169(4):887-99. doi: 10.1111/bph.12191. PubMed PMID: 23711022; PubMed Central PMCID: PMC3687668.

10: Ribeiro R, Wen J, Li S, Zhang Y. Involvement of ERK1/2, cPLA2 and NF-κB in microglia suppression by cannabinoid receptor agonists and antagonists. Prostaglandins Other Lipid Mediat. 2013 Jan;100-101:1-14. doi: 10.1016/j.prostaglandins.2012.11.003. Epub 2012 Dec 5. PubMed PMID: 23219970.

11: Paronis CA, Thakur GA, Bajaj S, Nikas SP, Vemuri VK, Makriyannis A, Bergman J. Diuretic effects of cannabinoids. J Pharmacol Exp Ther. 2013 Jan;344(1):8-14. doi: 10.1124/jpet.112.199331. Epub 2012 Sep 27. PubMed PMID: 23019138; PubMed Central PMCID: PMC3533417.

12: Lozano-Ondoua AN, Hanlon KE, Symons-Liguori AM, Largent-Milnes TM, Havelin JJ, Ferland HL 3rd, Chandramouli A, Owusu-Ankomah M, Nikolich-Zugich T, Bloom AP, Jimenez-Andrade JM, King T, Porreca F, Nelson MA, Mantyh PW, Vanderah TW. Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists. J Bone Miner Res. 2013 Jan;28(1):92-107. doi: 10.1002/jbmr.1732. PubMed PMID: 22903605; PubMed Central PMCID: PMC4745976.

13: Wood JT, Smith DM, Janero DR, Zvonok AM, Makriyannis A. Therapeutic modulation of cannabinoid lipid signaling: metabolic profiling of a novel antinociceptive cannabinoid-2 receptor agonist. Life Sci. 2013 Mar 19;92(8-9):482-91. doi: 10.1016/j.lfs.2012.06.019. Epub 2012 Jun 28. PubMed PMID: 22749867; PubMed Central PMCID: PMC3493696.

14: Su TF, Zhao YQ, Zhang LH, Peng M, Wu CH, Pei L, Tian B, Zhang J, Shi J, Pan HL, Li M. Electroacupuncture reduces the expression of proinflammatory cytokines in inflamed skin tissues through activation of cannabinoid CB2 receptors. Eur J Pain. 2012 May;16(5):624-35. doi: 10.1002/j.1532-2149.2011.00055.x. Epub 2011 Dec 19. PubMed PMID: 22337285.

15: Gamaleddin I, Zvonok A, Makriyannis A, Goldberg SR, Le Foll B. Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking. PLoS One. 2012;7(1):e29900. doi: 10.1371/journal.pone.0029900. Epub 2012 Jan 26. PubMed PMID: 22291896; PubMed Central PMCID: PMC3266883.

16: Tumati S, Largent-Milnes TM, Keresztes A, Ren J, Roeske WR, Vanderah TW, Varga EV. Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist. J Neuroimmunol. 2012 Mar;244(1-2):23-31. doi: 10.1016/j.jneuroim.2011.12.021. Epub 2012 Jan 30. PubMed PMID: 22285397; PubMed Central PMCID: PMC3298577.

17: Jiang S, Fu Y, Avraham HK. Regulation of hematopoietic stem cell trafficking and mobilization by the endocannabinoid system. Transfusion. 2011 Nov;51 Suppl 4:65S-71S. doi: 10.1111/j.1537-2995.2011.03368.x. PubMed PMID: 22074629.

18: Barutta F, Piscitelli F, Pinach S, Bruno G, Gambino R, Rastaldi MP, Salvidio G, Di Marzo V, Cavallo Perin P, Gruden G. Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes. 2011 Sep;60(9):2386-96. doi: 10.2337/db10-1809. Epub 2011 Aug 1. PubMed PMID: 21810593; PubMed Central PMCID: PMC3161308.

19: Curto-Reyes V, Boto T, Hidalgo A, Menéndez L, Baamonde A. Antinociceptive effects induced through the stimulation of spinal cannabinoid type 2 receptors in chronically inflamed mice. Eur J Pharmacol. 2011 Oct 1;668(1-2):184-9. doi: 10.1016/j.ejphar.2011.06.057. Epub 2011 Jul 13. PubMed PMID: 21771590.

20: Khasabova IA, Gielissen J, Chandiramani A, Harding-Rose C, Odeh DA, Simone DA, Seybold VS. CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain. Behav Pharmacol. 2011 Sep;22(5-6):607-16. doi: 10.1097/FBP.0b013e3283474a6d. PubMed PMID: 21610490; PubMed Central PMCID: PMC3155626.